Prof. Dr. Meltem Muftuoglu | Drug delivery Awards | Best Researcher Award

Prof. Dr. Meltem Muftuoglu | Drug delivery Awards | Best Researcher Award

Prof. Dr. Meltem Muftuoglu, Acibadem Mehmet Ali Aydinlar University, Turkey

Professor Meltem Muftuoglu is a distinguished molecular biologist and biochemist based at Acibadem Mehmet Ali Aydinlar University in Istanbul, Turkey. She holds dual professorships in the Departments of Molecular Biology and Genetics and Medical Biotechnology. Prof. Muftuoglu earned her Ph.D. in Biochemistry from Hacettepe University and has extensive research experience in molecular genetics and cellular medicine, including postdoctoral work at the NIH’s National Institute on Aging. Her work focuses on cancer drug delivery, mitochondrial targeting therapies, and DNA repair mechanisms, with numerous peer-reviewed publications in high-impact journals. An NIH and NATO A2 Scholar, she has received various awards, reflecting her significant contributions to biochemistry and molecular biology.

Professional Profile:

Scopus

Orcid

Suitability for the Best Researcher Award: Professor Meltem Muftuoglu

Summary of Suitability:

Professor Meltem Muftuoglu’s extensive academic and research career makes her an exemplary candidate for the Best Researcher Award. Her tenure at leading institutions, including her current professorship at Acibadem Mehmet Ali Aydinlar University in Istanbul, Turkey, underscores her commitment to advancing knowledge in molecular biology and medical biotechnology.

🎓Education:

Professor Meltem Muftuoglu holds a comprehensive academic background in biochemistry and biological sciences. She earned her B.Sc. in Biological Sciences in 1991 from Middle East Technical University in Ankara, Turkey. She then pursued graduate studies at Hacettepe University, Faculty of Medicine, where she completed an M.Sc. in Biochemistry in 1995 and subsequently a Ph.D. in Biochemistry in 2001. Recognized for her expertise, she received a docent degree in Biochemistry from the Higher Education Council in Ankara in 2005. Since 2015, Professor Muftuoglu has served as a Professor at Acibadem Mehmet Ali Aydinlar University in Istanbul, Turkey, where she contributes significantly to the fields of molecular biology and biotechnology.

🏢Work Experience:

Professor Meltem Muftuoglu has an extensive career in academia and research, marked by key positions across leading institutions worldwide. Since 2015, she has held a professorship at the Department of Molecular Biology and Genetics at Acibadem Mehmet Ali Aydinlar University in Istanbul, Turkey, and since 2018, she has also been a professor in the university’s Department of Medical Biotechnology. Prior to these roles, she served as an Associate Professor at the same university in Molecular Biology and Genetics (2014–2015) and at Koc University’s School of Medicine in the Department of Biochemistry (2011–2014). From 2009 to 2011, she was an Assistant Professor at the University of Copenhagen’s Department of Cellular and Molecular Medicine. Her research journey also includes a prestigious postdoctoral fellowship at the Laboratory of Molecular Gerontology, National Institute on Aging (NIH), in the United States (2004–2009). Additionally, she has served as an Assistant Professor in the Department of Biochemistry at Hacettepe University in Ankara, Turkey (2001–2004), and as a Research Scholar in the Laboratory of Molecular Genetics at the NIH’s National Institute on Aging (1999–2000). Earlier in her career, she was a Teaching and Research Assistant in Biochemistry at Hacettepe University (1993–2001), establishing a strong foundation for her distinguished work in biochemistry and molecular biology.

🏅Awards and Scholarships:

Throughout her career, Professor Meltem Muftuoglu has been recognized with numerous prestigious awards that highlight her contributions and commitment to scientific research. From 2004 to 2009, she was honored with the NIH Ruth L. Kirschstein National Research Service Award (NRSA), underscoring her excellence in research at the National Institute on Aging. In 2005, she was celebrated at the International Academy of Achievement Summit, reflecting her notable achievements in the field. Earlier, she was awarded the NATO A2 Scholarship by the Scientific and Technical Research Council of Turkey in 1998, and during 1999–2000, she received the NIH Fogarty Scholarship, further affirming her dedication to advancing biochemistry and molecular biology on a global scale.

🔬Research Focus:

Professor Muftuoglu’s research centers on advancing cancer therapeutics, mitochondrial targeting, and understanding DNA repair mechanisms. Her work in cancer drug delivery focuses on developing novel methods, including hydrophobin-coated and mitochondria-targeted liposomes, for more efficient and precise drug delivery to cancer cells. She is also exploring mitochondrial targeting therapies, which seek to selectively deliver drugs to mitochondria, enhancing both the efficacy and specificity of cancer treatments. Additionally, Professor Muftuoglu investigates DNA repair mechanisms, particularly base excision repair pathways, to uncover genetic factors that impact diseases like Alzheimer’s and various cancers.

Publication Top Notes:

  • Cosmic Whirl: Navigating the Comet Trail in DNA: H2AX Phosphorylation and the Enigma of Uncertain Significance Variants
  • Formulation Development and Evaluation of Fluvastatin Loaded Transethosomes: Characterization, Stability, In Vitro Dermal Penetration, Cytotoxicity and Antipsoriatic Activity Studies
    • Citations: 1
  • Targeting Mitochondrial DNA Polymerase Gamma for Selective Inhibition of MLH1 Deficient Colon Cancer Growth
    • Citations: 8
  • Leukocyte Telomere Length as a Compensatory Mechanism in Vitamin D Metabolism
    • Citations: 3
  • Parents of Ataxia-Telangiectasia Patients Display a Distinct Cellular Immune Phenotype Mimicking ATM-Mutated Patients
    • Citations: 5

 

 

 

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Assist. Prof. Dr. Mohamed skiba, University of rouen, France

Dr. Mohamed Skiba, is a French national and a distinguished pharmaceutical scientist. He is a lecturer at the Faculty of Medicine and Pharmacy in Rouen, where he leads the Pharmaceutical Team within the Galenic Group. Dr. Skiba earned his Ph.D. in Pharmaceutical Sciences from the University of Paris XI in 1994 and has been active in pharmaceutical research since 1990, focusing on cyclodextrin and drug vectorization. With over 140 international publications, 80 patents, and numerous contributions to books and congresses, he is a recognized expert in pharmaceutical technology. Dr. Skiba is also an active member of several scientific societies, including the French Society of Chemistry and the French Association of Teachers of Technological Pharmacy. He is fluent in French, English, and Arabic.

Professional Profile:

Orcid

Suitability for Best Innovation Award: Dr. Mohamed SKIBA

Dr. Mohamed Skiba’s extensive work in pharmaceutical sciences, particularly his research in drug formulation and cyclodextrin technologies, positions him as a strong candidate for the Best Innovation Award. His innovations, reflected in his numerous patents and publications, highlight his ability to drive pharmaceutical advancements with real-world applications. His leadership in academic and research institutions further amplifies his impact, making him a deserving recipient of this prestigious award.

🎓Education:

Dr. Mohamed Skiba holds a Ph.D. in Pharmaceutical Sciences, which he earned in 1994 from the University of Paris XI, Southern Paris. His academic journey also includes a Diploma of Thorough Studies in Pharmacotechnology and Biopharmacy (1990) from the University of Paris XI in Châtenay-Malabry. In 1990, he obtained a Diploma in Veterinary Pharmaceuticals from the Faculty of Pharmacy, University of Clermont-Ferrand I. Additionally, Dr. Skiba completed advanced studies in pharmacology and electrophysiology with a Control of Research degree from the University of Poitiers in 1989. He also pursued studies in patent rights at the Faculty of Orsay, University of Paris-South, enriching his expertise in pharmaceutical and intellectual property matters.

🏢Work Experience:

Dr. Mohamed Skiba has been a lecturer at the Faculty of Medicine and Pharmacy, University of Rouen, France, since 1998. In this role, he teaches courses in galenic and industrial galenic pharmacy to both undergraduate and graduate students, while also leading the Pharmaceutical Team within the Galenic Group. His professional experience includes serving as a trainee at the Central Pharmacy of the Hospitals of Paris (PCH) and working as an Associated Attaché in Toxicology and Clinical Pharmacology at the Hospital of Corbeil-Essonnes, further enhancing his expertise in pharmaceutical technology and clinical applications.

🏅Awards & Recognition:

Dr. Mohamed Skiba is a prolific contributor to the field of pharmaceutical technology, holding over 80 patents that highlight his innovative work. He has authored 140 international publications and contributed to 9 book chapters, making significant scholarly impacts. Additionally, Dr. Skiba has presented 71 communications at prestigious scientific congresses, sharing his research and advancements with the global scientific community.

🔬Research Focus:

Dr. Skiba’s research primarily centers on pharmaceutical technology, with a particular focus on cyclodextrin and drug vectorization. His work involves improving drug delivery systems, studying bio-polymeric materials, and developing innovative pharmaceutical formulations. He has been involved in numerous pharmaceutical research projects since 1990, contributing to the advancement of drug delivery and formulation technologies.

Publication Top Notes:

  • Powder Self-Emulsifying Drug Delivery System for Mitotane: In Vitro and In Vivo Evaluation
  • In vitro dissolution of encapsulated or dispersed vitamin E and cholesterol is correlated with preservation of refrigerated ovine sperm
  • Exploring the Therapeutic Potential of Algerian Propolis: GC/MS Profiling, Protective Inclusion Complex, and In Silico Evaluation Against SARS‐CoV‐2 Main Proteases
  • Development of a Novel Cyclodextrin–Chitosan Polymer for an Efficient Removal of Pharmaceutical Contaminants in Aqueous Solution

 

 

Assoc. Prof. Dr. Kyeong Soo Kim | Pharmaceutics Awards | Excellence in Research

Assoc. Prof. Dr. Kyeong Soo Kim | Pharmaceutics Awards | Excellence in Research

Assoc. Prof. Dr. Kyeong Soo Kim  , Gyongsang National University/Dept. of Pharmaceutical Engineering , South Korea

Kyeong Soo Kim is an accomplished researcher and academic based in the Republic of Korea. He currently serves as an Associate Professor in the Department of Pharmaceutical Engineering at Gyeongsang National University. Dr. Kim earned his Ph.D. in Pharmacy from Hanyang University, where he specialized in the development of novel controlled release formulations for fenofibric acid. His research interests span nanotechnology applications for poorly water-soluble drugs, improved pharmaceutical technologies for controlled release dosage forms, inhaled drug delivery systems, and dermal drug delivery systems. Prior to his current position, he held roles as a Postdoctoral Research Associate at the University of Mississippi and as a Principal Scientist at Hanmi Pharm. Co., Ltd., where he gained extensive experience in formulation and process development. Dr. Kim’s expertise includes designing oral and parenteral dosage forms, conducting preformulation studies, and utilizing advanced techniques such as solid dispersion, spray drying, and lipid-based formulations to enhance drug delivery efficacy. He is actively involved in research and has contributed significantly to the field through his publications and professional engagements.

Professional Profile:

Scopus

🎓Education:

Kyeong Soo Kim is a distinguished academic and researcher in the field of pharmacy, currently holding the position of Associate Professor at Gyeongsang National University in the Republic of Korea. He completed his Ph.D. in Pharmacy at Hanyang University from March 2011 to August 2015, under the guidance of Professor Han-Gon Choi, Ph.D. His doctoral research focused on the development of innovative controlled release formulations for fenofibric acid. Prior to his doctoral studies, he earned a Master of Science in Pharmacy at Chungbuk National University from March 2002 to August 2004, where his research investigated the depigmenting effects and mechanisms of piperlonguminine derived from Piper longum. Kyeong Soo Kim began his academic journey with a Bachelor of Science in Pharmacy, also from Chungbuk National University, completed from March 1998 to February 2002. His educational background underscores his expertise in pharmaceutical sciences, particularly in drug delivery systems and formulation development.

 🏢Work Experience:

Kyeong Soo Kim is currently an Associate Professor in the Department of Pharmaceutical Engineering at Gyeongsang National University in the Republic of Korea, a position he has held since September 2017. Prior to joining Gyeongsang National University, Dr. Kim served as a Postdoctoral Research Associate at the Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, USA, from September 2016 to August 2017. Before his time in the United States, he worked as a Postdoctoral Research Fellow at the Laboratory of Industrial & Physical Pharmacy at Hanyang University, Republic of Korea, from September 2015 to August 2016. Dr. Kim’s extensive professional experience also includes a significant tenure as a Principal Scientist and Team Manager at the Pharmaceutical R&D Center of Hanmi Pharm. Co., Ltd., Republic of Korea, where he contributed from August 2004 to November 2014. His career path highlights his expertise in pharmaceutical engineering, drug delivery systems, and research leadership in both academic and industrial settings.

Publication Top Notes:

  • “Improved bioavailability and high photostability of methotrexate by spray-dried surface-attached solid dispersion with an aqueous medium” by Giri, B.R., Kim, J.S., Park, J.H., … Choi, H.G., Kim, D.W.
    • Journal: Pharmaceutics, 2021, 13(1), pp. 1–14, 111
    • Citations: 36
  • “Nitration of protein phosphatase 2A increases via Epac1/PLCε/CaMKII/HDAC5/iNOS cascade in human endometrial stromal cell decidualization” by Lee, S.Y., Lee, Y.Y., Choi, J.-S., … Park, S.-Y., Han, J.-S.
    • Journal: FASEB Journal, 2020, 34(11), pp. 14407–14423
    • Citations: 2
  • “Development of Novel d-Cycloserine Tablet with Improvement of Drug Stability and Dissolution-Equivalence to the d-Cycloserine-Loaded Commercial Hard Capsule” by Kim, J.S., Choi, Y.J., Woo, M.R., … Jin, S.G., Choi, H.-G.
    • Journal: Bulletin of the Korean Chemical Society, 2020, 41(6), pp. 603–608
    • Citations: 3
  • “Enhanced Chemical Stability of D-Cycloserine via Tablet Form Containing Magnesium Oxide as an Alkali Stabilizer” by Kim, J.S., Lee, S.M., Kim, D.S., … Jin, S.G., Choi, H.-G.
    • Journal: Bulletin of the Korean Chemical Society, 2020, 41(1), pp. 10–14
    • Citations: 1
  • “Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate” by Kim, D.S., Cho, J.H., Park, J.H., … Choi, H.-G., Kim, D.W.
    • Journal: International Journal of Nanomedicine, 2019, 14, pp. 4949–4960
    • Citations: 61